You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康方生物(09926.HK)將公布包括兩項目LBA研究在內6項最新研究進展
阿思達克 10-28 12:59
康方生物(09926.HK)宣布,將在2020年11月10日至15日線上舉辦的第35屆腫瘤免疫治療學會年會(SITC 2020)上,公布6項與公司產品相關的最新研究資料,包括以突破性成果(LBA)研究形式公布派安普利單抗(AK105,PD-1)兩項臨床試驗進展,以及以海報形式介紹CD47單抗(AK117)、CD73單抗(AK119) 、TIGIT單抗(AK127)以及PD-1/CD73(AK123)雙抗的最新研究進展。

其中,以LBA研究形式發布派安普利單抗(PD-1)的兩項臨床研究,標題分別是:《PD-1單抗派安普利在二線及以上已接受化療治療的轉移性鼻咽癌患者中開展的單臂、開放、多中心II期臨床研究》和《PD-1單抗派安普利在復發或難治性經典型霍奇金淋巴瘤患者中開展的II期臨床研究》。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account